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Purpose: To evaluate changes in retinal layer thickness in patients with Type 1 diabetes
with no diabetic retinopathy after 8 years of follow-up.
Methods: Ninety Type 1 diabetes and 60 control eyes were studied. Changes in the
retinal nerve fiber layer, ganglion cell layer, and inner nuclear layer thicknesses in all Early
Treatment Diabetic Retinopathy Study areas were evaluated.
Results: The mean ages were 42.93 ± 13.62 and 41.52 ± 13.05 years in the diabetic and
control group, respectively. In 2009, total retinal thickness was higher in diabetic patients;
differences were statistically significant in all except the nasal areas. In both groups, the
mean foveal thickness remained the same during the 8 years. Among diabetic patients,
there was a significant reduction in total retinal thickness in all areas excluding the outer
temporal one; controls only in the inferior areas. The thickness loss was due to the thinning
of the inner retinal layers (inner nuclear layer, ganglion cell layer, and retinal nerve fiber
layer). The controls showed a significant diminution in the retinal nerve fiber layer and in the
ganglion cell layer areas. The inner nuclear layer showed a diminution in the diabetes
mellitus group.
Conclusion: Before the onset of diabetic retinopathy, Type 1 diabetes patients
experience a diminution of their inner retinal layer thicknesses over time, supporting the
hypothesis of retinal neurodegeneration.
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Although diabetic retinopathy (DR) is the majorcause of visual loss in Type 1 diabetes patients,
it is not the only cause of visual dysfunction. It has
been proven that functional changes affecting the ret-
inal cells exist before the microvascular changes. This
dysfunction is secondary to a neurodegenerative pro-
cess and to the loss of retinal neurons. Diabetic neuro-
degeneration has been diagnosed using different
functional indicators including color perception,1,2
diminished contrast sensitivity,3–5 reduction in dark
adaptation,5 electroretinogram changes such as reduc-
tion in oscillatory potential or abnormal multifocal
pattern electroretinogram,6–11 abnormal electrophysio-
logical tests,12–17 and defects in the retinal nerve fiber
layer (RNFL) with concurrent defects in the visual
field.18–23 Neuronal changes can be studied and quan-
tified using spectral domain optical coherence tomog-
raphy (SD-OCT) thickness and volume. Optical
coherence tomography allows for the visualization of
the retinal layers, their segmentation, and a quantitative
mapping of the studied layer.
Neurodegeneration can be studied by looking for
changes in the different neurons or in the RNFL. The
loss of retinal neurons generates a secondary loss of
the synaptic circuitry that transmits information to the
central nervous system.
Various authors have demonstrated a diminution of
retinal macular thickness before the development of
DR,23–25 mainly due to a reduction of the ganglion cell
layer (GCL)–inner plexiform layer and RNFL in both
Type 1 and Type 2 diabetic patients.26 To the best of
our knowledge, no one has yet demonstrated, in a ret-
rospective study with a long follow-up time, inner
retinal layer (IRL) changes in a diabetic population not
1
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yet showing vascular changes. Sohn et al27 showed
that the loss of the RNFL and GCL–inner plexiform
layer during 4 years of follow-up using Stratus OCT in
a Type 1 diabetic population with no or minimal dia-
betic lesions correlates with similar findings in animal
models and postmortem immunohistochemistry.
The purpose of our study was to assess IRL thickness
changes in Type 1 diabetic patients with no retinopathy
changes after 8 years of follow-up. The aim was to
demonstrate the presence of a progressive neurodegen-
eration before the signs of DR.
Methods
One hundred twenty-two eyes from 122 diabetes
mellitus (DM) patients with no DR were studied by SD-
OCT in 2009. The eyes were reexamined by SD-OCT
looking for changes in macular thickness. Patients were
studied at the Miguel Servet University Hospital and
Lozano Blesa University Hospital in Zaragoza, Spain.
All of the procedures were conducted in accordance
with the principles of the Helsinki declaration, and the
experimental protocol was approved by the local ethics
committee (CEICAAU4 ). Detailed consent forms were ob-
tained from each patient.
The criteria for inclusion in the diabetic group were
a Type 1 diabetes diagnosis and no retinal changes evident
by biomicroscopy. The control group included healthy
age-matched subjects. All controls had a best-corrected
visual acuity greater than 20/25 on the Snellen chart, with
refractive errors between +3.75 and 26.75 diopters.
Exclusion criteria were the presence of any sign of
DR or retinopathy of other origin, glaucoma, or
intraocular pressure over 21 mmHg assessed by
Goldmann tonometry, optic nerve pathology, ocular
inflammation, or any ocular surgery or procedure
including laser therapy, ocular traumatism, anterior
segment pathology, or media opacification. All the
diabetic patients were followed up by the endocrinol-
ogy unit during this time, and blood samples were
analyzed every 6 months. Arterial blood pressure and
lipid values were maintained under extreme control.
All of the subjects underwent a complete ophthal-
mic exploration including medical, ocular, and family
history, best-corrected visual acuity with the Early
Treatment Diabetic Retinopathy Study (ETDRS) chart,
slit-lamp examination, intraocular pressure measure-
ment with Goldmann applanation tonometry, and
fundoscopy examination.
Each individual was imaged using the Spectralis
OCT (Heidelberg Engineering, Inc, Heidelberg, Ger-
many) device. Volume fast macula scanning was
performed. The subject was asked to look into the
internal fixation target for measurement with Tru-Track
eye tracking technology. A second examination (2017)
was scheduled for follow-up. Spectralis OCT provides
a circular macular map analysis, which is composed of
9 sectorial thickness measurements in 3 concentric
circles, with diameters of 1, 3 (inner), and 6 (outer) mm,
forming the 9 areas corresponding to the ETDRS.28 The
following regional macular thicknesses were analyzed:
fovea (1 mm, R1), temporal inner (T1), superior inner
(S1), nasal inner (N1), inferior inner (I1), temporal outer
(T2), superior outer (S2), nasal outer (N2), and inferior
outer (I2). The Spectralis software version was 6.8.1.0.
Segmentation was performed automatically by the
device in both images; measurements included the inner
and outer retina divided by the external limiting mem-
brane (ELM) and the different IRLs including the
RNFL, GCL, inner plexiform layer, and inner nuclear
layer (INL) ( F1Figure 1). The IRL thickness was mea-
sured from the internal limiting membrane (ILM) to
the ELM, and the outer retinal layer (ORL) thickness
was measured from the ELM to the Bruch membrane
(BM). The scan quality and segmentation accuracy
were assessed before the analysis, and scans with poor
quality were rejected. The threshold for image quality
was at least 25 over 40 dB.
All of the statistical analysis was performed using
SPSS (SPSS 22.0, SPSS, Chicago, IL). Temporal
parameters (2017 vs. 2009) were compared by the
nonparametric Wilcoxon test, and the mean values by
groups within the same year were analyzed by the
Kolmogorov–Smirnov test. A P value , 0.05 was
considered statistically significant.
Results
From the 122 Type 1 diabetes patients studied in
2009, 32 patients failed to complete the study (four of
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them died from causes that were not related to their
diabetes, all of them from hematologic neoplasms). In
addition, 16 eyes developed retinal changes before
2017 and were excluded, and thus, 12 patients did not
continue with the study. Ultimately, 90 eyes from 90
patients were analyzed. Sixty eyes from 60 normal
age-matched subjects served as a control group. The
mean age in the control group was 42.41 ± 13.56 years
(range 26–68); the mean in the diabetic group was
41.52 ± 13.05 years (range 22–65). Female subjects
accounted for 46.7% of the Type 1 diabetes group and
65% of the control group.
The mean length of diabetes evolution at the 2017
exploration time was 24.88 ± 8.42 years (range 9–40
years). The diabetic population showed a mean HbA1c
value of 7.73 ± 1.22% in 2009 and 7.76 ± 1.06% in
2017. Blood pressure and lipid values were maintained
in normal limits.
In 2017, ophthalmological evaluation of the control
group showed 20.113 ± 0.097 logarithm of the min-
imum angle of resolution (logMAR) (26/20 Snellen)
mean best-corrected visual acuity with 100% ETDRS
chart, +0.21 ± 0.18 logMAR (12/20 Snellen) with
2.5% ETDRS chart, and +0.32 ± 2.27 logMAR
(10/20 Snellen) with 1.25% ETDRS chart. Ophthal-
mological evaluation of the diabetic group showed
20.13 ± 0.11 logMAR (27/20 Snellen) with 100%
ETDRS chart, 0.35 ± 0.16 logMAR (9/20 Snellen)
with 2.5% ETDRS chart, and 0.35 ± 2.87 logMAR
(9/20 Snellen) with 1.25% ETDRS chart. At follow-
up, the mean intraocular pressure was 16.59 ± 2.27
mmHg and 16.82 ± 2.87 mmHg in the control and
diabetic groups, respectively.
In 2009, total retinal thicknesses were higher in the
diabetic group than in the control group; differences
were statistically significant in all the areas (P, 0.05),
including the central retina, except in the parafoveal
nasal (N1). These differences were mainly due to IRL
thickness, and in the ORL, there was only difference in
I2. In 2017, the only areas in which statistically sig-
nificant differences were found between the diabetic
and control group were the central retina (R1) and in
Table 1. Total Retina Thickness, IRL (From ILM to ELM), and ORL (From ELM to BM) in DM vs. Controls, for the Two Time
Points (2017 and 2009)
DM vs. Control in 2009 DM vs. Control in 2017
Total
Retina
IRLs
(ILM–ELM)
Outer Retinal
Layers (ELM–BM)
Total
Retina
IRLs
(ILM–ELM)
Outer Retinal
Layers (ELM–BM)
Foveal center (ETDRS central
region: R1, 1 mm)
0.005* 0.046* 0.884 0.030* 0.030* 0.143
Inner circle (ETDRS
paracentral region: 3 mm)
Superior S1 0.024* 0.045* 0.423 0.269 0.236 0.660
Temporal T1 0.013* 0.002* 0.976 0.068 0.060 0.561
Inferior I1 0.009* 0.016* 0.766 0.276 0.250 0.977
Nasal N1 0.056 0.033* 0.649 0.213 0.109 0.947
Outer circle (ETDRS
pericentral region: 6 mm)
Superior S2 0.006* 0.035* 0.363 0.004* 0.010* 0.939
Temporal T2 0.027* 0.053 0.460 0.259 0.070 0.989
Inferior I2 0.001* 0.003* 0.044* 0.009* 0.005* 0.051
Nasal N2 0.238 0.369 0.090 0.440 0.633 0.178
Statistically significant differences found between the DM group and control group are shown in bold and with an asterisk (*) for the
ETDRS regions evaluated (foveal center, inner circle, and outer circle). Differences were mainly found in the IRL.
Fig. 1. Cross-sectional B scan
demonstrating the reference
lines used for analysis. Left,
original reference lines; right,
magnified view of the lines.
OPL, outer plexiform layer; PR,
pneumatic retinopexy.
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external vertical sectors (S2 and I2). These differences
were located in the IRL (T1 Tables 1 and 2).
Table 2 showsT2 that the mean retinal subfoveal
thickness remained the same during the 8-year
follow-up period. The values for the control and dia-
betic group were 277.63 ± 17.96 mm versus 286.60 ±
23.90 mm in 2009, respectively, and 279.28 ± 16.36
mm versus 288.28 ± 28.59 mm in 2017, respectively.
In the diabetic patients, there was a significant reduc-
tion in total retinal thickness in all of the ETDRS
areas excluding the outer temporal (T2) area; the con-
trol group showed a thickness decrease only in both
inferior areas (I1 and I2). The thickness loss was
mainly due to the thinning of the IRL that was sig-
nificantly reduced in all areas of the diabetic patients
excluding the central and outer temporal (T2) areas
(T3 Table 3), as reflected in the total retinal thickness
values (Table 1). Globally, the thickness diminution
was seen in RNFL, GCL, and INL, and the regions
achieving statistically significant differences between
evaluations are shown in gray on the map of the
different ETDRS areas (F2 Figure 2). The control group
showed preserved IRL thickness in all areas except
the outer vertical areas (S2 and I2), and ORL re-
mained the same in all areas except S1 in controls
and T2 in the DM group (T4 Table 4).
Loss of GCL and RNFL was found in both diabetic
and healthy subjects (Figure 2). Looking at the para-
central areas (N1, S1, T1, and I1) where the GCL
bodies are located, the control group showed loss in
both the S1 and I1 zones, and diabetic patients showed
loss in all of these sectors. Looking at the RNFL in the
perifoveal areas, where the fibers are predominantly
located, the control group again showed loss in the
I2 and S2 regions, as well as in N2, whereas the dia-
betic patients showed loss in the T2, I2, and N2
sectors.
The loss of the different layers by ring during the 8
years of follow-up was calculated. In the control
group, the mean GCL loss was 20.076 mm/year in
the parafoveal ring; no loss of RNFL was found in the
perifoveal areas during this time. Inner nuclear layer
loss in the control group was 20.053 mm/year in the
perifoveal area with no changes in the parafoveal
area. Diabetic patients lost 20.182 mm/year in the
GCL of the parafoveal ring, and they did not show
loss of the mean perifoveal RNFL. The INL of the
diabetic patients lost 20.111 mm/year and 20.126
mm/year in the perifoveal and parafoveal areas,
respectively.
The outer retinal layer (comprising the ELM
and the retinal pigment epithelium) was mainly
preserved in both groups during the 8 years of
follow-up.
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Discussion
In our study, we observed an early impairment of
the neurosensorial retina in Type 1 diabetic patients
with no DR signs, manifesting as a diminution of the
total inner retina. At the beginning of the study, we
observed that the diabetic group presented a thicker
total retina due to an increase in IRL thickness, but
these differences disappeared during the study
follow-up. This increase in retina thickness has been
explained by different theories: changes in the blood–
retinal barrier, modification in different cell types such
as endothelial cells or pericytes, Müller cells, or other
glial cells; all these changes could be related to the
hyperglycemia.29–33
Neurodegeneration in diabetic eyes before the onset
of the microvascular changes is a proven fact.34 Var-
ious authors have shown a reduced GCL in diabetic
patients with no DR, both in Type 1 and 2 diabetes.
Demirkaya et al35 found a loss of GCL and RNFL in
a small number of diabetic patients with no signs of
DR (n = 19). Scarinci et al36 demonstrated an early
impairment of the neurosensorial retina with an
increased INL yet a decrease in the GCL, in Type 1
diabetic patients with no changes or minimal impair-
ment. In our patients, we found loss at the GCL level
not only in the diabetic group but also in the vertical
areas of the control subjects. Loss of thickness at the
RNFL has been previously reported in patients with no
or minimal retinal changes.20–22 In our retrospective
study, we have demonstrated that Type 1 diabetic pa-
tients lose internal retina, including all IRL from the
ILM to the ELM. Ganglion cell layers and their fibers
are lost not only in diabetic patients before the onset of
the retinopathy changes but also in healthy subjects in
this age range after 8 years. Demirkaya et al35 demon-
strated the loss in RNFL and GCL related to age using
SD-OCT. Van Dijk used the SD-OCT algorithm (Iowa
Reference Algorithm) to describe the same finding in
Type 1 and 2 diabetic patients with no or minimal
diabetic lesions.37,38 Looking at the parafoveal areas
(N1, S1, T1, and I1) where most ganglion cell bodies
are located, the control group showed GCL loss
mainly in the vertical areas (S1 and I1); diabetic pa-
tients showed loss in all of the paracentral areas.
The total rate of parafoveal loss in both groups was
higher in the diabetic than in the control group
(20.182 mm/year vs. 20.076 mm/year). The retinal
nerve fiber layer is located in pericentral ETDRS areas.
Looking at these peripheral areas, both healthy and
diabetic subjects showed fiber loss in almost all of
the areas. Vertical sectors (S2 and I2) are the ones that
are more affected in healthy subjects. The retinal nerve
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fiber layer is expected to be lost first at the nasal region
of the peripheral (N2) area, but this finding was com-
mon to both the control group and diabetic patients.39
Using the total value of the RNFL in the 4 pericentral
areas, we did not find any loss during the 8 years, not
only in the control group but also in the diabetic group
as well. The distribution of the RNFL in vertical areas
with less fibers and more separation between them
make them more susceptible to the damage, as it hap-
pens in other diseases.40 Park et al41 found that both
RNFL and GCL in the superior quadrants had a higher
fiber and cell loss. They explained their findings were
due to a lower perfusion in this area. The biggest
change in our studied groups was at the INL level:
In the perifoveal area, the loss was 20.053 mm/year
versus 20.111 mm/year in the control and diabetic
group, respectively. Only the diabetic patients had loss
in the parafoveal area, at a rate of 20.126 mm/year,
whereas the controls remained unaltered in this area.
These changes in the INL could be related to the loss
of the GCL as a sign of the retrograde degeneration.
Sohn et al27 had similar findings in a smaller pop-
ulation including minimal retinal changes in a 4-year
follow-up period. The strength of their study was the
ability to correlate the OCT findings with the IRL
thinning in a diabetic rodent model. Their results are
provided using Stratus, a time-domain OCT. Spectral
domain optical coherence tomography has a much bet-
ter resolution of the retinal structures in these small
values of the retinal layers.
The loss of the IRL could support the perifoveal
capillary loss seen in both Type 1 and 2 diabetic patients
before the onset of diabetic retinal changes. Dimitrova
et al42 showed a significant decrease in both the superficial
and deep capillary plexus using OCTA in diabetic patients
before the onset of lesions (mainly Type 2 diabetic pa-
tients). The foveal avascular zone was increased in the
superficial plexus supporting the inner vascular changes.
Vujosevic et al43 showed this capillary loss in the super-
ficial capillary plexus and an increase in the foveal avas-
cular zone supporting the changes in the IRL. The authors
showed a decrease in the inner retinal thickness values,
but the results did not reach significant levels.
Subfoveal thickness is generated by cones and
Müller cell bodies. It has no relation to the amount
of ganglion cells. We did not find glial cell diminution
Fig. 2. Thickness maps showing differences in the RNFL, the GCL, and the INL in the different ETDRS areas corresponding to a right eye, with
temporal areas on the left and nasal areas on the right, in DM and the control group. Significant changes after 8 years of follow-up are shown in gray
(P , 0.05).
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at this level. The absence of changes during the 8 years
of follow-up in our study supports the hypothesis that
the number of cones at the foveal level is well main-
tained during a long time interval. Other explanations
could be the Müller cell activation or thickening of the
retinal pigment epithelium that appears with age, but
the mean age of our population was relatively young
for this retinal pigment epithelium aging explanation.
The IRL is a part of the central nervous system.
Changes in the central nervous system have been
found in long-standing Type 1 diabetic patients with
decreased functional connectivity and cognition,44
suggesting that chronic hyperglycemia can damage
neural function with long-term diabetic status, as seen
in our study.
Patients included in our study had good glycemic
control. Other concomitant diseases that could affect
the results were excluded. Lipid levels and arterial
tension were extremely well controlled, eliminating
potential confounders. None of the diabetic patients
showed kidney dysfunction or peripheral neuropathy.
Conclusion
In conclusion, before the onset of DR, Type 1
diabetic patients can present an increased retinal
thickness due to IRL thickening. Patients experience
a diminution of their retinal thicknesses over time,
mainly in their IRL, supporting the hypothesis of
retinal neurodegeneration in the diabetic patient.
Key words: diabetic retinopathy, ganglion cell
layer, inner nuclear layer, inner retinal layers, neuro-
degeneration, ophthalmology, retinal nerve fiber layer,
retinal thickness, spectral domain optical coherence
tomography, Type 1 diabetes mellitus. AU3
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